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The story of coro-
nary intervention
is a very compelling
one and should be
well understood by
physicians, patients,
and payers, . . .
The positive aspects
of the coronary in-
terventional story
need emphasis.
In the near future,
more and more
revascularization
cases will be per-
formed as hybrid
procedures taking
advantage of arte-
rial grafting and
stenting (which
may eventually
prove superior to
vein grafting).DITOR’S PAGE
etting Over the Siege Mentality
Interventional cardiology is under attack.” I hear this phrase frequently from my colleagues
nd those in the industries that develop and market much of the technology we use. I think
e should get over the mindset that we are victims, not because it is completely untrue, but
ecause it is unproductive. What is the evidence that there are those who oppose interven-
ional cardiology?
The volume of interventional cardiology cases has stopped increasing in the U.S. overall, and
any laboratories have seen their case volumes going down. Case load for peripheral vascular
nd structural heart disease cases has not followed this path but the bread-and-butter of inter-
entional cardiology (i.e., coronary stenting) has. Some studies have suggested that coronary
tenting is unnecessary, and medical therapy only is as good or better. Guidelines and appro-
riateness documents continue to be updated and revised, but there is an impression that they
ay not reflect the outcomes of the most current interventional methods and may not contain
he latest evidence.
In responding to the perception that our subspecialty is under siege, we sometimes react in
ess than productive ways. The story of coronary intervention is a very compelling one and
hould be well understood by physicians, patients, and payers, and if we hold to the evidence
nd build on it with appropriate investigation, it will continue to be.
We must not get trapped into the argument that interventions are “superior to medical or
urgical therapies.” This generalization is no more correct than the inverse or the incorrect as-
umption that aspirin and statins are appropriate for the entire population because of statistical
ignificance driven by the subpopulations that really need them.
Why have stent volumes moderated? There are perhaps several reasons:
. The market was oversold. That is, the use of stenting in the U.S. was twice that of other
developed countries, and the growth from this level was unsustainable.
. Drug-eluting stenting has resulted in less restenosis, less repeat procedures, and therefore
fewer stents.
. Referring physicians and patients were persuaded that stenting did not “fix” the problem
and prevent events.
. The largely unjustified fear that stenting is associated with a significant increase in arterial
thrombosis was prevalent.
. Increasing appreciation of the potential to stabilize coronary atherosclerosis with appropri-
ately targeted medical therapies is a reality for many patients.
Whereas some of these are reasonable and some are in need of clarification and education,
here is no need for interventionalists to become defensive.
The positive aspects of the coronary interventional story need emphasis.
. Acute myocardial infarction is best treated with stenting, period. The guidelines attempt to
reflect evidence of how this can be accomplished through primary percutaneous coronary
intervention when available and transfer percutaneous coronary intervention when it can be
streamlined.
. Angina due to obstructive epicardial coronary artery disease and documented ischemia is
most effectively treated with stenting, when technically feasible. The FAME trial, which
studied the predictive value of fractional flow reserve, and other evidence should not be
viewed as a reason to avoid physiological assessment of ischemic but rather as documenta-
tion of the effectiveness of coronary intervention to eliminate ischemia.
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580Which defensive arguments are not selling?
. The “oculostenotic” assertion that since there is a le-
sion it may get worse.
. The “vulnerable plaque” may be lurking and, therefore,
stenting is needed even for nonobstructive lesions. Yes,
methods of predicting sites of arterial thrombosis lead-
ing to acute myocardial infarction and frequently death
should receive great attention, but we do not currently
have proof that these can be predicted, or if they are,
what therapy can prevent the catastrophic event.
. Stenting will provide improved longevity compared
with other therapeutic methods. We simply do not
have the studies to establish that, although our im-
proving techniques certainly seem to be pointing to-
ward more parity with surgical methods.
As with any confrontation we should recognize the en-
my. In this case, it is the destructive disease of coronary
therosclerosis. In order to fight any battle all resources
eed to be brought to bear. In war, the ground, air, and
ea forces may be needed to defeat an enemy. In the case
f our enemy, medical therapy, interventional methods, snd surgery all play vital roles. In the near future, more
nd more revascularization cases will be performed as hy-
rid procedures taking advantage of arterial grafting and
tenting (which may eventually prove superior to vein
rafting). Effective methods to stabilize coronary disease
re here and need to be applied in a more focused per-
onalized way. However, relief of ischemia will always be
chieved most effectively by restoring the plumbing.
We should not fear “comparative effectiveness re-
earch” but insist that studies be designed to evaluate
hose patients who actually have the need for the ther-
pies tested. The contribution of interventional cardio-
ascular medicine makes a compelling story. We have
o need to be defensive.
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